Display Settings:

Format

Send to:

Choose Destination
    Int J Dermatol. 2003 Feb;42(2):123-9.

    Acral lentiginous melanoma: an immunohistochemical study of 20 cases.

    Source

    Department of Dermatology and Pathology, Dankook University, College of Medicine, Cheonan, Chungcheong Nam Do, Korea. kyccc@dku.edu

    Abstract

    BACKGROUND:

    Though acral lentiginous melanoma (ALM) is a major type of malignant melanoma, no immunohistochemical study on this type of melanoma has been reported.

    OBJECTIVE:

    The purpose of this study is to analysis the immunohistochemical findings of ALM using routinely used immune markers.

    METHODS:

    An immunohistochemical study was performed on paraffin sections of 20 ALMs using S-100 protein, HMB-45, MART-1, vimentin, epithelial membrane antigen (EMA) and CAM 5.2.

    RESULTS:

    S-100 protein (95%) was found to be a more sensitive marker than either HMB-45 (80%) or MART-1 (70%) for recognizing ALM. Melanin bleaching was useful for recognizing heavily pigmented ALM using both S-100 protein and HMB-45. The intensity of HMB-45 correlated well with the melanin content. However, there was no significant correlation between the intensity of S-100 protein and the melanin content. One and two out of 20 cases stained focally with EMA and CAM5.2, respectively, but these cases stained also with HMB-45 and/or S-100 protein.

    CONCLUSIONS:

    S-100 protein and HMB-45 were relatively sensitive markers for recognizing ALM. Despite the occasional positivity for the epithelial markers in ALM, all epithelial marker-positive cases stained also with HMB-45 and/or S-100 protein. Therefore, we recommend that the panel of antibodies used for recognizing ALM should contain at least S-100 protein and HMB-45.

    PMID:
    12709000
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Click here to read

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk